Cargando…

Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety

BACKGROUND: Osteomyelitis is a challenging infection that can involve 4–6 weeks of intravenous (IV) antibiotics. Dalbavancin, approved for acute bacterial skin and skin structure infections, has potent activity against gram-positive pathogens. This study assessed the efficacy and safety of dalbavanc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rappo, Urania, Puttagunta, Sailaja, Shevchenko, Vadym, Shevchenko, Alena, Jandourek, Alena, Gonzalez, Pedro L, Suen, Amy, Mas Casullo, Veronica, Melnick, David, Miceli, Rosa, Kovacevic, Milan, De Bock, Gertjan, Dunne, Michael W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6326511/ https://www.ncbi.nlm.nih.gov/pubmed/30648126 http://dx.doi.org/10.1093/ofid/ofy331

Ejemplares similares

Safety of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Nephrotoxicity Rates Compared with Vancomycin: A Post Hoc Analysis of Three Clinical Trials
por: Gonzalez, Pedro L., et al.
Publicado: (2021)

Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials
por: Gonzalez, Pedro L., et al.
Publicado: (2021)

Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs
por: Gonzalez, Pedro Luis, et al.
Publicado: (2018)

Epithelial Lining Fluid and Plasma Concentrations of Dalbavancin in Healthy Adults after a Single 1,500-Milligram Infusion
por: Rappo, Urania, et al.
Publicado: (2019)

267 Dalbavancin for the treatment of Streptococcal Skin Infections
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infection in Patients With Obesity or Diabetes: A Subgroup Analysis of Pooled Phase 3 Clinical Trials
por: Riccobene, Todd, et al.
Publicado: (2023)

Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studies
por: Dunne, Michael W, et al.
Publicado: (2015)

Effectiveness of Dalbavancin Compared With Standard of Care for the Treatment of Osteomyelitis: A Real-world Analysis
por: Cain, Alexander R, et al.
Publicado: (2021)

Necrotizing Fasciitis Within 72 hours After Presentation with Skin and Skin Structure Infection
por: Rappo, Urania, et al.
Publicado: (2020)

Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies
por: Dunne, Michael W., et al.
Publicado: (2015)

266 Dalbavancin vs Vancomycin for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a subanalysis from the DISCOVER studies
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

Pharmacokinetics, Safety, and Tolerability of a Single 500-mg or 1000-mg Intravenous Dose of Dalbavancin in Healthy Japanese Subjects
por: Scoble, Patrick J., et al.
Publicado: (2015)

A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection
por: Dunne, Michael W., et al.
Publicado: (2016)

279. Dalbavancin for Bloodstream Infections and Endocarditis: Real-World Outcomes From the DRIVE Registry
por: Gonzalez, Pedro, et al.
Publicado: (2020)

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Obese Population
por: Georgiades, Benjamin, et al.
Publicado: (2017)

1660. Dalbavancin Utilization Registry Investigating Value and Effectiveness (DRIVE): Outcomes Report on Real-World Use
por: Jones, Bruce M, et al.
Publicado: (2022)

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in Patients with Diabetes Mellitus
por: Nowak, Michael, et al.
Publicado: (2017)

Successful Treatment of Diabetic Foot Osteomyelitis with Dalbavancin
por: Loupa, Chariclia V., et al.
Publicado: (2020)

Sulopenem for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis: A Phase 3, Randomized Trial
por: Dunne, Michael W, et al.
Publicado: (2022)

Sulopenem or Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Phase 3, Randomized Trial
por: Dunne, Michael W, et al.
Publicado: (2022)

Comparison of Sequential Dalbavancin With Standard-of-Care Treatment for Staphylococcus aureus Bloodstream Infections
por: Molina, Kyle C, et al.
Publicado: (2022)

1000. Antimicrobial Susceptibility of Gram-Positive Bacteria Isolated From Patients Hospitalized With Bacteremia in United States and European Medical Centers: Results From the International Dalbavancin Evaluation of Activity (IDEA) Program
por: Sader, Helio S, et al.
Publicado: (2018)

Long-term Dalbavancin for Suppression of Gram-Positive Chronic Left Ventricular Assist Device Infections
por: Rowe, Sarah, et al.
Publicado: (2023)

108. Efficacy of Dalbavancin Compared to Standard of Care for the Treatment of Osteomyelitis: A Retrospective Study
por: Cain, Alexander, et al.
Publicado: (2021)

971. Pharmacokinetic Estimation Analysis of Multi-Dose Regimens of Dalbavancin for Treatment of Osteomyelitis or Bacteremia
por: Volk, Cecilia, et al.
Publicado: (2023)

Diagnostic Efficacy of Diffusion-weighted Imaging in Distinguishing Chronic Diffuse Sclerosing Osteomyelitis from Suppurative Osteomyelitis of the Mandible
por: Muraoka, Hirotaka, et al.
Publicado: (2022)

Dalbavancin
por: Barberán, José, et al.
Publicado: (2021)

Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial
por: Turner, Nicholas A., et al.
Publicado: (2022)

Dalbavancin for treatment of implant-related methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model
por: Kussmann, Manuel, et al.
Publicado: (2018)

Dalbavancin versus standard of care for the treatment of osteomyelitis in adults: A retrospective matched cohort study
por: Almangour, Thamer A., et al.
Publicado: (2020)

Pressure Ulcer-Related Pelvic Osteomyelitis: A Neglected Disease?
por: Bodavula, Phani, et al.
Publicado: (2015)

Microbial Etiology of Pyogenic Vertebral Osteomyelitis According to Patient Characteristics
por: Kim, Dong Youn, et al.
Publicado: (2020)

1393. A Phase 1, Randomized, Open-Label, Crossover Study in Healthy Subjects Under Fasting Conditions of Orally Administered Sulopenem Etzadroxil Alone or with Probenecid to Determine the Pharmacokinetics of Sulopenem
por: Dunne, Michael, et al.
Publicado: (2018)

1527. The Prevalence of Enterobacteriaceae (ENT) Resistant to All Major Classes of Oral Antibiotics from Outpatient Urine Cultures in the United States and Effect on Clinical Outcomes
por: Dunne, Michael, et al.
Publicado: (2018)

Effectiveness of Casirivimab and Imdevimab Antibody Combination in Immunocompromised Hospitalized Patients With Coronavirus Disease 2019: A Post Hoc Analysis in a Phase 1/2/3 Double–Blind Trial
por: Somersan-Karakaya, Selin, et al.
Publicado: (2023)

Long-Term Outcome of Pyogenic Vertebral Osteomyelitis: A Cohort Study of 260 Patients
por: Gupta, Arjun, et al.
Publicado: (2014)

Globicatella sanguinis Osteomyelitis and Bacteremia: Review of an Emerging Human Pathogen with an Expanding Spectrum of Disease
por: Miller, Andy O., et al.
Publicado: (2017)

Percutaneous Bone Biopsy for Diabetic Foot Osteomyelitis: A Systematic Review and Meta-Analysis
por: Schechter, Marcos C, et al.
Publicado: (2020)

The STAPH Score: A Predictor of Staphylococcus aureus as the Causative Microorganism of Native Vertebral Osteomyelitis
por: Matsuo, Takahiro, et al.
Publicado: (2020)

Short Antibiotic Treatment Duration for Osteomyelitis Complicating Pressure Ulcers: A Quasi-experimental Study
por: Dinh, Aurélien, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jalvennn80v53tpu9ng2bhpcsu